Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN) News
Filter BHVN News Items
BHVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BHVN News Highlights
- For BHVN, its 30 day story count is now at 25.
- Over the past 23 days, the trend for BHVN's stories per day has been choppy and unclear. It has oscillated between 1 and 11.
- MG, PFE and CRS are the most mentioned tickers in articles about BHVN.
Latest BHVN News From Around the Web
Below are the latest news stories about Biohaven Pharmaceutical Holding Co Ltd that investors may wish to consider to help them evaluate BHVN as an investment opportunity.
Aerie, Schrodinger top healthcare gainers; while Baudax Bio, The Joint lead losers' packGainers: Aerie Pharmaceuticals (NASDAQ:AERI) +25%. Schrodinger (NASDAQ:SDGR) +17%. MDxHealth (NASDAQ:MDXH) +16%. Lantheus (NASDAQ:LNTH) +13%. Tabula Rasa HealthCare (NASDAQ:TRHC) +13%. Losers: Baudax Bio (NASDAQ:BXRX) -55%. The Joint (NASDAQ:JYNT) -15%. Biohaven Pharmaceutical (NYSE:BHVN) -8%. Ginkgo Bioworks (NYSE:DNA) -8%. Revelation Biosciences (NASDAQ:REVB) -4%.... |
Biohaven Pharmaceuticals Non-GAAP EPS of -$2.32 misses by $0.39, revenue of $190.01M beats by $14.47MBiohaven Pharmaceuticals press release (NYSE:BHVN): Q4 Non-GAAP EPS of -$2.32 misses by $0.39. Revenue of $190.01M (+441.2% Y/Y) beats by $14.47M.... |
Biohaven Pharmaceutical Holding's (BHVN) CEO Vlad Coric on Q4 2021 Results - Earnings Call TranscriptBiohaven Pharmaceutical Holding Company Ltd. (BHVN) Q4 2021 Earnings Conference Call February 25, 2022 8:30 AM ET Company Participants Caroline Dircks – Vice President, Corporate Operations Vlad Coric – Chief Executive Officer Matthew Buten – Chief Financial Officer BJ Jones – Chief Commercial Officer Elyse Stock – Chief Medical Officer... |
Biohaven Pharmaceutical Holding Company Ltd. 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Biohaven Pharmaceutical Holding Company Ltd. in conjunction with their 2021 Q4 earnings call.... |
Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising DealsBiohaven inked a pair of deals Friday to outfit its pipeline with several new drugs, but BHVN stock plummeted on quarterly losses. |
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences DealsView more earnings on BHVNSee more from BenzingaBlood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study ShowsModerna Adds Three New mRNA-Based Development Programs To Its Pipeline© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. |
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue EstimatesBiohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -45.41% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTSBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a review of accomplishments during 2021 and anticipated upcoming milestones. |
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine TreatmentBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, recommending the 75 mg dose of rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and th |
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp BiosciencesBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive agreement to acquire Channel Biosciences, LLC, a subsidiary of Knopp Biosciences LLC, and its Kv7 channel targeting platform – adding the latest advances in ion-channel modulation to Biohaven's growing neuroscience portfolio. The Kv7 platform has been developed and refined for over a decade by a team with deep experience in ion channel science led by Michae |